Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration

Seminars in Ophthalmology

Volumn 26, Issue 6, 2011, Pages 361-371

  Shultz, Ryan W ^a   Bakri, Sophie J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticoagulation; Neovascularization; Pneumatic; Subretinal; TPA; Vitrectomy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; CLOPIDOGREL; PERFLUTREN; RANIBIZUMAB; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE; VERTEPORFIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; MONOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; SUBMACULAR HEMORRHAGE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; HUMANS; PHOTOCHEMOTHERAPY; PRESSURE; RETINAL HEMORRHAGE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 80455168303     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.585368     Document Type: Article

References (63)

1. Hochman M, Seery C, Zarbin M. Pathophysiology and management of subretinal haemorraghe. Surv Ophthalmol 1997; 41:195-213.
2. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol. 1996; 122:486-493.
3. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762-773.
4. Toth CA, Morse LS, Hjemeland LM, et al. Fibrin early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723-729
5. Scupola A, Cosca G, Soubrane G, et al. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97-102.
6. Bennet SR, Folk JC, Blodi CF, et al. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990;109:33-37.
7. Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16:183-189.
8. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, MacCumber MW, Marsh MJ, Redford M, Sternberg P Jr., Thomas MA, Williams GA, Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmol. 2004 Nov; 111(11):1993-2006.
9. Schulze SD, Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: Predictive variable for visual outcome. Graefes Arch Clin Exp Ophthalmol 2002;240: 717-720.
10. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol. 1994;118:559-68.
11. Hattenbach LO, Klais C, Koch FH, Gumbel HO. Intravitreous injection of tissue plaminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmol 2001;108:1485-92.
12. Olivier S, Chow DR, Packo KH, MacCumber MW, Awh CC. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmol. 2004 Jun; 111(6):1201-8.
13. Lewis H, Sloan SH, Foos RY. Massive intraocular hemorrhage associated with anticoagulation and age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1988;226:59-64.
14. el Baba J, Jarett WH II, Harbin TS Jr., et al. Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants. Ophthalmol 1986;93:1581-1592.
15. Tilanus MA, Vaandrager W, Cuypers MH, Verbeek AM, Hoyng CB. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2000 Jun; 238(6):482-5.
16. Kuhli-Hattenbach C et al. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol. 2010;149:316-321.
17. Kiernan D, Hariprasad S, Rusu I, Mehta S, Mieler W, Jager R. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular agerelated macular degeneration. Retina 2010;30:1573-1578.
18. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136:407-418.
19. Bakri SJ, Nickel J, Yoganathan P, Beer PM. Photodynamic therapy for choroidal neovascularization associated with submacular hemorrhage in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006 Jul-Aug;37(4):278-83.
20. Ruiz-Moreno, B. Triamcinolone and PDT to treat exudative ARMD and submacular hemorrhage. Eur J Ophth 2006; 16:426-434.
21. Ahmad S, Bearelly S, Fekrat S, et al. Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration. Am J Ophthalmol. 2008; 145(6):1052-1057.
22. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.
23. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 2006;355:1432-1444.
24. Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
25. Chang M, et al. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 2010; 30:1171-1176.
26. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007; 144: 886-892.
27. Sacu S, Stifter E, Vecsei-Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye. 2009;23 (6):1404-1410.
28. Heriot WJ. Intravitreal gas and TPA: An outpatient procedure for submacular hemorrhage. AAO 1996 OR Vail Vitrectomy Meeting, Vail, CO.
29. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmol. 1999;106:1900-1907.
30. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999;237: 273-277.
31. Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue of tissue plasminogen activator and expansile gas. Retina 2007; 27:321-328.
32. Ohji M, Saito Y, Hayashi A, Lewis J, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326-1332.
33. Gopalakrishan M, Giridhar A, Bhat S, Saikumar SJ, Elias A, N S. Pneumatic displacement of submacular hemorrhage: Safety, efficacy, and patient selection. Retina. 2007 Mar; 27(3):329-34.
34. Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: A retrospective pilot study. Acta Ophthalmol Scand. 2008;86 (5):490-494.
35. Cakir M, Cekic O, Yilmaz O. Pneumatic displacement of acute submacular hemorrhage with and without the use of tissue plasminogen activator. Eur J Ophthalmol 2010; 20:565-571.
36. Lincoff H, Kreissig I, Stopa M, Uram D. A 40o gaze down position for pneumatic displacement of submacular hemorrhage. Retina. 2008;28:56-59.
37. De Juan E Jr., Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol. 1988;105:25-29.
38. Wade EC, Flynn HW Jr., Olsen KR, et al. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol. 1990;109:973-978.
39. Vander JF, Federman JL, Greven C, et al. Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmol. 1991;98:23-27.
40. Peyman GA, Nelson NC Jr., Alturki W, Blinder KJ, Paris CL, Desai UR, Harper CA 3rd. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg. 1991 Oct; 22(10):575-82.
41. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 cases. Arch Ophthalmol. 1995;113:62-69.
42. Moriarty AP, McAllister IL, Constable IJ. Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Eye. 1995; 9:582-588.
43. Kamei M, Tano Y, Maeno T, et al. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol. 1996;121:267-275.
44. Haupert CL, McCuen BW 2nd, Jaffe GJ, Steuer ER, Cox TA, Toth CA et al Pars plana victrectomy, subretinal injection of plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001;131 (2):208-215.
45. Lüke M, Januschowski K, Warga M, et al. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007;91:1077-82.
46. Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol 2010; 94:48-53.
47. Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010 Feb18;4:67-72.
48. Sandhu SS, Manvikar S, Steel DH. Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab. Clin Ophthalmol. 2010 Jul 21;4:637-42.
49. Hillenkamp J, Surguch V, Framme C, Gabel V, Sachs H. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2010;248:5-11.
50. Oshima Y, Ohji M, Tano Y. Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: A modified procedure to drain massive subretinal haemorrhage. Br J Ophthalmol. 2007; 91:193-198.
51. Fine HF, Iranmanesh R, Del Priore LV, Barile GR, Chang LK, Chang S, Schiff WM. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. 2010 Nov-Dec; 30 (10):1588-94.
52. Ma Z, Han L, Wang C, et al. Autologous transplantation of retinal pigment epithelium-Bruch's membrane complex for hemorrhagic age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:2975-2981.
53. Wong D, Stanga P, Briggs M, et al. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol 2004;88:186-190.
54. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
55. Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991;111:197-204.
56. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 1991;11:250-258.
57. Chen SN, Yang TC, Ho CL, et al. Retinal toxicity of intravitreal tissue plasminogen activator: Case report and literature review. Ophthalmol 2003;110 (4):704-708.
58. Boone DE, Boldt CH, Ross RD, et al. The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model. Retina 1996; 16:518-524.
59. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-326.
60. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999; 128:739-746.
61. Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina 2007 Oct;27(8):1071-3.
62. Takeuchi A, Kricorian G, Yao X, Kenny J, Marmor M. The rate and source of albumin entry into saline filled experimental retinal detachment. Invest Ophthalmol Vis Sci 1994; 25:3792-3798.
63. Kwan S, Vijayasekaran S, McAllister I, Yu P, Yu D. A study of retinal penetration of intravitreal tenecteplase in pigs. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2662-2667.